Pear Therapeutics to Participate in Upcoming Investor Event Hosted by Credit Suisse

Rhea-AI Summary

Pear Therapeutics, Inc. (NASDAQ: PEAR), a leader in prescription digital therapeutics (PDTs), will participate in the Credit Suisse Hidden Gems Conference on April 7 in New York, NY. The company's management will be available for one-on-one meetings with institutional investors. Pear Therapeutics aims to redefine healthcare with clinically validated PDTs, boasting FDA-approved products like reSET® for substance use disorder, reSET-O® for opioid use disorder, and Somryst® for insomnia. For more details, visit www.peartherapeutics.com.

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced the company will participate in the Credit Suisse The Investor Landscape: Hidden Gems Conference on Thursday, April 7 in New York, NY.

Management will be available for one-on-one meetings with institutional investors. Portfolio managers and analysts wishing to request a meeting should contact their institutional sales representative at Credit Suisse.

About Pear Therapeutics

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET^®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O^®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst^® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005232/en/

Media and Investors:

Meara Murphy

Senior Director, Corporate Communications

meara.murphy@peartherapeutics.com

Source: Pear Therapeutics, Inc.

FAQ

What will Pear Therapeutics present at the Credit Suisse Hidden Gems Conference on April 7?

Pear Therapeutics will participate in the Credit Suisse Hidden Gems Conference and engage in one-on-one meetings with institutional investors.

What is the focus of Pear Therapeutics as a company?

Pear Therapeutics focuses on developing and commercializing prescription digital therapeutics (PDTs) to improve patient outcomes.

What products has Pear Therapeutics received FDA approval for?

Pear Therapeutics has received FDA approval for reSET®, reSET-O®, and Somryst®, the first PDTs for treating substance use disorder, opioid use disorder, and chronic insomnia respectively.

How can investors and analysts contact Pear Therapeutics for meetings?

Investors and analysts can contact their institutional sales representative at Credit Suisse to request a meeting.

Where can I find more information about Pear Therapeutics?

More information about Pear Therapeutics can be found on their website at www.peartherapeutics.com.